Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.00 and traded as low as $3.69. Oramed Pharmaceuticals shares last traded at $3.79, with a volume of 435 shares trading hands.

Separately, HC Wainwright reiterated a “buy” rating on shares of Oramed Pharmaceuticals in a report on Wednesday, June 19th.

The stock has a fifty day simple moving average of $3.51. The company has a market cap of $65.70 million, a P/E ratio of -4.40 and a beta of 1.37.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.71 million. Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. On average, equities analysts forecast that Oramed Pharmaceuticals, Inc. will post -0.98 EPS for the current fiscal year.

In related news, Director Leonard Sank bought 20,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was bought at an average price of $3.47 per share, for a total transaction of $69,400.00. Following the completion of the acquisition, the director now directly owns 315,482 shares in the company, valued at $1,094,722.54. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have acquired 25,817 shares of company stock valued at $91,009. 27.70% of the stock is owned by company insiders.

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. BlackRock Inc. grew its position in shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,343 shares of the biotechnology company’s stock after purchasing an additional 40,114 shares during the quarter. BlackRock Inc. owned approximately 0.40% of Oramed Pharmaceuticals worth $208,000 as of its most recent SEC filing. 6.18% of the stock is owned by institutional investors.

About Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Read More: Market Capitalization and Individual Investors

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.